Puma Biotechnology (United States)

Institution (Company)

Homepage ROR

Also Known As

Puma Biotechnology (United States)

1.1K

Publications

48.2K

Citations

Authors

100

Concepts

About

Puma Biotechnology (United States) is a company institution in Los Angeles, United States known for medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	186	24.5K
2	Health Sciences	7	43	10.9K
3	Natural Sciences	3	3	106
4	Engineering	2	2	114
5	Public Health	1	32	4.5K

Puma Biotechnology (United States)

1.1K

Publications

48.2K

Citations

Page 1

	Year	Citations
HER kinase inhibition in patients with HER2- and HER3-mutant cancers David M. Hyman, Sarina A. Piha‐Paul, Helen Won, Nature Tumor BiologyOncologyMedicineReceptor Tyrosine KinasePathology	2018	752
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Journal of Clinical Oncology	2020	588
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Arlene Chan, Suzette Delaloge, Frankie A. Holmes, The Lancet Oncology Breast OncologyHealth SciencesMedicineClinical TrialsImmune Checkpoint Inhibitor	2016	551
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer Ahmad Awada, Rámón Colomer, Kenichi Inoue, JAMA Oncology	2016	310
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia Michelle L. Churchman, Jonathan Low, Chunxu Qu, Cancer Cell Hematological MalignancyMixed-phenotype Acute LeukemiaMedicineCell BiologyCancer Research	2015	211
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial Arlene Chan, Beverly Moy, Janine Mansi, Clinical Breast Cancer	2020	211
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer X. Cynthia, Ron Bose, Feng Gao, Clinical Cancer Research	2017	188
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis, Journal of Clinical Oncology	2016	153
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis Aadya Nagpal, Richard P. Redvers, Xiawei Ling, Breast Cancer Research	2019	148

Page 1